Company Overview More
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
CEO: Hallam Ph.D., Thomas M.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > PALI Palisade Bio > Detailed Quotes

PALI Palisade Bio

0.530+0.025+4.85%
Trading Session 05/16 11:00 ET
High
0.540
Open
0.540
Turnover
16.88K
Low
0.510
Pre Close
0.506
Volume
32.46K
Market Cap
11.60M
P/E(TTM)
Loss
52wk High
4.570
Shares
21.88M
P/E(Static)
Loss
52wk Low
0.400
Float Cap
7.15M
Bid/Ask %
-53.85%
Historical High
792.000
Shs Float
13.49M
Volume Ratio
0.26
Historical Low
0.400
Dividend TTM
--
Div Yield TTM
--
P/B
2.42
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.24%
Amplitude
5.93%
Avg Price
0.519
Lot Size
1
Float Cap
7.15M
Bid/Ask %
-53.85%
Historical High
792.000
Shs Float
13.49M
Volume Ratio
0.26
Historical Low
0.400
Dividend TTM
--
P/B
2.42
Dividend LFY
--
Turnover Ratio
0.24%
Amplitude
5.93%
Avg Price
0.519
Lot Size
1
Price Forecast

Loading...

News

Comment